Androgen receptor roles in the development of benign prostate hyperplasia

American Journal of Pathology

Volumn 182, Issue 6, 2013, Pages 1942-1949

  Izumi, Kouji ^a,b   Mizokami, Atsushi ^b   Lin, Wen Jye ^a   Lai, Kuo Pao ^a   Chang, Chawnshang ^a,c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b KANAZAWA UNIVERSITY   (Japan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; DUTASTERIDE; FINASTERIDE; FLUTAMIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TESTOSTERONE;

ANTIANDROGEN THERAPY; CELL GROWTH; CELL INTERACTION; CELL POPULATION; CELL PROLIFERATION; DRUG EFFICACY; DRUG SAFETY; EJACULATION DISORDER; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; ERECTILE DYSFUNCTION; EXPERIMENTAL MODEL; FIBROBLAST; HUMAN; INFLAMMATION; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MACROPHAGE MIGRATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE VOLUME; REVIEW; SMOOTH MUSCLE FIBER; STROMA CELL; URINARY TRACT OBSTRUCTION;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; CELL COMMUNICATION; CELL PROLIFERATION; EPITHELIAL CELLS; HUMANS; MALE; MICE; PROSTATIC HYPERPLASIA; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 84878261153     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.02.028     Document Type: Review

References (73)

1. J.T. Wei, E. Calhoun, and S.J. Jacobsen Urologic diseases in America project: benign prostatic hyperplasia J Urol 173 2005 1256 1261
2. P. Ekman BPH epidemiology and risk factors Prostate Suppl 2 1989 23 31
3. S.A. Ahyai, P. Gilling, S.A. Kaplan, R.M. Kuntz, S. Madersbacher, F. Montorsi, M.J. Speakman, and C.G. Stief Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement Eur Urol 58 2010 384 397
4. R.D. Smith, and A. Patel Transurethral resection of the prostate revisited and updated Curr Opin Urol 21 2011 36 41
5. L.E. Kavanagh, G.S. Jack, and N. Lawrentschuk Prevention and management of TURP-related hemorrhage Nat Rev Urol 8 2011 504 514
6. A. Kapoor Benign prostatic hyperplasia (BPH) management in the primary care setting Can J Urol 19 Suppl 1 2012 10 17
7. H. Lepor, A. Kazzazi, and B. Djavan alpha-Blockers for benign prostatic hyperplasia: the new era Curr Opin Urol 22 2012 7 15
8. M. Emberton, J.M. Fitzpatrick, and J. Rees Risk stratification for benign prostatic hyperplasia (BPH) treatment BJU Int 107 2011 876 880
9. J. Barkin Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management Can J Urol 18 Suppl 2011 14 19
10. T.M. van der Sluis, E.J. Meuleman, R.J. van Moorselaar, H.N. Bui, M.A. Blankenstein, A.C. Heijboer, and A.N. Vis Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer BJU Int 109 2012 183 188
11. E. Bierhoff, J. Vogel, M. Benz, T. Giefer, N. Wernert, and U. Pfeifer Stromal nodules in benign prostatic hyperplasia Eur Urol 29 1996 345 354
12. P. Alonso-Magdalena, C. Brössner, A. Reiner, G. Cheng, N. Sugiyama, M. Warner, and J.A. Gustafsson A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia Proc Natl Acad Sci USA 106 2009 2859 2863
13. JW. White I. The results of double castration in hypertrophy of the prostate Ann Surg 22 1895 1 80
14. M. Elhilali, J.G. Lehoux, M. Carmel, P. Madarnas, C. Mongeau, C. Beauchesne, L. Tétreault, and B. Bénard Nuclear androgen receptors of human prostatic tissue-a quantitative histological study Arch Androl 10 1983 21 27
15. R. Horton, P. Hsieh, J. Barberia, L. Pages, and M. Cosgrove Altered blood androgens in elderly men with prostate hyperplasia J Clin Endocrinol Metab 41 1975 793 796
16. G.L. Hammond, M. Kontturi, P. Vihko, and R. Vihko Serum steroids in normal males and patients with prostatic diseases Clin Endocrinol (Oxf) 9 1978 113 121
17. C.H. Liao, H.Y. Li, S.D. Chung, H.S. Chiang, and H.J. Yu Significant association between serum dihydrotestosterone level and prostate volume among Taiwanese men aged 40-79 years Aging Male 15 2012 28 33
18. J. Tang, J.C. Yang, Y. Zhang, X. Liu, L. Zhang, Z. Wang, J. Li, Y. Luo, J. Xu, and H. Shi Does benign prostatic hyperplasia originate from the peripheral zone of the prostate? A preliminary study BJU Int 100 2007 1091 1096
19. N. Kyprianou, and P. Davies Association states of androgen receptors in nuclei of human benign hypertrophic prostate Prostate 8 1986 363 380
20. C.A. Peters, and E.R. Barrack Androgen receptor localization in the human prostate: demonstration of heterogeneity using a new method of steroid receptor autoradiography J Steroid Biochem 27 1987 533 541
21. M. Krieg, W. Bartsch, M. Thomsen, and K.D. Voigt Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate J Steroid Biochem 19 1983 155 161
22. S. Tunn, H. Hochstrate, I. Grunwald, S.H. Flüchter, and M. Krieg Effect of aging on kinetic parameters of 5 alpha-reductase in epithelium and stroma of normal and hyperplastic human prostate J Clin Endocrinol Metab 67 1988 979 985
23. S. Monti, F. Di Silverio, V. Toscano, C. Martini, S. Lanzara, P.A. Varasano, and F. Sciarra Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH) J Androl 19 1998 428 433
24. F.H. Schroeder, M. Westerhof, R.J. Bosch, and K.H. Kurth Benign prostatic hyperplasia treated by castration or the LH-RH analogue buserelin: a report on 6 cases Eur Urol 12 1986 318 321
25. S. Bianchi, G. Gravina, A. Podestà, D. Barletta, F. Franchi, P. Kicovic, and M. Luisi Treatment of complicated benign prostatic hyperplasia with LHRH-analogues in aged patients Int J Androl 12 1989 104 109
26. N.N. Stone, and S.J. Clejan Response of prostate volume, prostate-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasia J Androl 12 1991 376 380
27. M. Jønler, M. Riehmann, and R.C. Bruskewitz Benign prostatic hyperplasia. Current pharmacological treatment Drugs 47 1994 66 81
28. D.K. Wysowski, J.P. Freiman, J.B. Tourtelot, and M.L. Horton 3rd Fatal and nonfatal hepatotoxicity associated with flutamide Ann Intern Med 118 1993 860 864
29. C.M. Tempany, A.W. Partin, E.A. Zerhouni, S.J. Zinreich, and P.C. Walsh The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia Prostate 22 1993 39 42
30. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group Prostate 22 1993 291 299
31. P. Grino, and E. Stoner Finasteride for the treatment and control of benign prostatic hyperplasia: summary of phase III controlled studies. The Finasteride Study Group Eur Urol 25 Suppl 1 1994 24 28
32. L.S. Marks, A.W. Partin, G.J. Gormley, F.J. Dorey, E.D. Shery, J.B. Garris, E.N. Subong, E. Stoner, and J.B. deKernion Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia J Urol 157 1997 2171 2178
33. T. Shirakawa, H. Okada, B. Acharya, Z. Zhang, N. Hinata, Y. Wada, T. Uji, S. Kamidono, and A. Gotoh Messenger RNA levels and enzyme activities of 5 alpha-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue Prostate 58 2004 33 40
34. R.V. Clark, D.J. Hermann, G.R. Cunningham, T.H. Wilson, B.B. Morrill, and S. Hobbs Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor J Clin Endocrinol Metab 89 2004 2179 2184
35. C.G. Roehrborn, P. Siami, J. Barkin, R. Damião, K. Major-Walker, I. Nandy, B.B. Morrill, R.P. Gagnier, F. Montorsi CombAT Study Group The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study [Erratum appeared in Eur Urol 2010, 58:801] Eur Urol 57 2010 123 131
36. F. Montorsi, C. Roehrborn, J. Garcia-Penit, M. Borre, T.A. Roeleveld, J.C. Alimi, P. Gagnier, and T.H. Wilson The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study BJU Int 107 2011 1426 1431
37. A.M. Traish, J. Hassani, A.T. Guay, M. Zitzmann, and M.L. Hansen Adverse side effects of 5alpha-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients J Sex Med 8 2011 872 884
38. R.S. Kirby, C. Roehrborn, P. Boyle, G. Bartsch, A. Jardin, M.M. Cary, M. Sweeney, E.B. Grossman Prospective European Doxazosin and Combination Therapy Study Investigators Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial Urology 61 2003 119 126
39. C.A. Byrnes, A.S. Morton, C.L. Liss, M.C. Lippert, and J.Y. Gillenwater Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar Clin Ther 17 1995 956 969
40. H. Lepor, W.O. Williford, M.J. Barry, M.K. Brawer, C.M. Dixon, G. Gormley, C. Haakenson, M. Machi, P. Narayan, and R.J. Padley The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group N Engl J Med 335 1996 533 539
41. M.J. Marberger Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group Urology 51 1998 677 686
42. C.G. Roehrborn, P. Siami, J. Barkin, R. Damião, K. Major-Walker, B. Morrill, F. Montorsi CombAT Study Group The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study [Erratum appeared in J Urol 2008, 180:1191] J Urol 179 2008 616 621 discussion 621
43. D. Bello, M.M. Webber, H.K. Kleinman, D.D. Wartinger, and J.S. Rhim Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18 Carcinogenesis 18 1997 1215 1223
44. I.S. Silva, D.M. Morsch, L. Urnauer, and P.M. Spritzer Androgen-induced cell growth and c-myc expression in human non-transformed epithelial prostatic cells in primary culture Endocr Res 27 2001 153 169
45. C.T. Wu, S. Altuwaijri, W.A. Ricke, S.P. Huang, S. Yeh, C. Zhang, Y. Niu, M.Y. Tsai, and C. Chang Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor [Erratum appeared in Proc Natl Acad Sci U S A 2007, 104:17240] Proc Natl Acad Sci USA 104 2007 12679 12684
46. M.R. Feneley, J.R. Puddefoot, S. Xia, C. Sowter, G. Slavin, R.S. Kirby, and G.P. Vinson Zonal biochemical and morphological characteristics in BPH Br J Urol 75 1995 608 613
47. A. Svindland, L.M. Eri, and K.J. Tveter Morphometry of benign prostatic hyperplasia during androgen suppressive therapy. Relationships among epithelial content, PSA density, and clinical outcome Scand J Urol Nephrol Suppl 179 1996 113 117
48. C.W. Bayne, F. Donnelly, K. Chapman, P. Bollina, C. Buck, and F. Habib A novel coculture model for benign prostatic hyperplasia expressing both isoforms of 5 alpha-reductase [Erratum appeared in J Clin Endocrinol Metab 1998, 83:910] J Clin Endocrinol Metab 83 1998 206 213
49. D.M. Peehl, and J.S. Rubin Keratinocyte growth factor: an androgen-regulated mediator of stromal-epithelial interactions in the prostate World J Urol 13 1995 312 317
50. K. Nakano, Y. Fukabori, N. Itoh, W. Lu, M. Kan, W.L. McKeehan, and H. Yamanaka Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10 Endocr J 46 1999 405 413
51. P. Nisticò, M.J. Bissell, and D.C. Radisky Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases Cold Spring Harb Perspect Biol 4 2 2012
52. K. Wu, and B. Bonavida The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs Crit Rev Immunol 29 2009 241 254
53. M. Iwatsuki, K. Mimori, T. Yokobori, H. Ishi, T. Beppu, S. Nakamori, H. Baba, and M. Mori Epithelial-mesenchymal transition in cancer development and its clinical significance Cancer Sci 101 2010 293 299
54. E. Slabáková, Z. Pernicová, E. Slavíč ková, A. Staršíchová, A. Kozubík, and K. Souček TGF-beta1-induced EMT of non-transformed prostate hyperplasia cells is characterized by early induction of SNAI2/Slug Prostate 71 2011 1332 1343
55. Z.L. Wu, Y. Yuan, H. Geng, and S.J. Xia Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue Asian J Androl 14 2012 316 319
56. T. Lu, W.J. Lin, K. Izumi, X. Wang, D. Xu, L.Y. Fang, L. Li, Q. Jiang, J. Jin, and C. Chang Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development Mol Endocrinol 26 2012 1707 1715
57. Q. Jiang, B.M. Han, F.J. Zhao, Y. Hong, and S.J. Xia The differential effects of prostate stromal cells derived from different zones on prostate cancer epithelial cells under the action of sex hormones Asian J Androl 13 2011 798 805
58. S. Monti, F. Di Silverio, R. Iraci, C. Martini, S. Lanzara, P. Falasca, M. Poggi, A. Stigliano, F. Sciarra, and V. Toscano Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens J Clin Endocrinol Metab 86 2001 1700 1706
59. C. Sáez, A.C. González-Baena, M.A. Japón, J. Giráldez, D.I. Segura, J.M. Rodríguez-Vallejo, J. González-Esteban, G. Miranda, and F. Torrubia Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride Prostate 40 1999 83 88
60. S. Yu, C. Zhang, C.C. Lin, Y. Niu, K.P. Lai, H.C. Chang, S.D. Yeh, C. Chang, and S. Yeh Altered prostate epithelial development and IGF-1 signal in mice lacking the androgen receptor in stromal smooth muscle cells Prostate 71 2011 517 524
61. S. Yu, C.R. Yeh, Y. Niu, H.C. Chang, Y.C. Tsai, H.L. Moses, C.R. Shyr, C. Chang, and S. Yeh Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts Prostate 72 2012 437 449
62. K.P. Lai, S. Yamashita, S. Vitkus, C.R. Shyr, S. Yeh, and C. Chang Suppressed prostate epithelial development with impaired branching morphogenesis in mice lacking stromal fibromuscular androgen receptor Mol Endocrinol 26 2012 52 66
63. B. Fibbi, G. Penna, A. Morelli, L. Adorini, and M. Maggi Chronic inflammation in the pathogenesis of benign prostatic hyperplasia Int J Androl 33 2010 475 488
64. L.A. Begley, S. Kasina, J. MacDonald, and J.A. Macoska The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy Cytokine 43 2008 194 199
65. X. Wang, W.J. Lin, K. Izumi, Q. Jiang, K.P. Lai, D. Xu, L.Y. Fang, T. Lu, L. Li, S. Xia, and C. Chang Increased infiltrated macrophages in benign prostatic hyperplasia (BPH): role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferation J Biol Chem 287 2012 18376 18385
66. S. Yamashita, K.P. Lai, K.L. Chuang, D. Xu, H. Miyamoto, T. Tochigi, S.T. Pang, L. Li, Y. Arai, H.J. Kung, S. Yeh, and C. Chang ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors Neoplasia 14 2012 74 83
67. K.P. Lai, S. Yamashita, C.K. Huang, S. Yeh, and C. Chang Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro-inflammatory cytokines/chemokines EMBO Mol Med 4 2012 791 807
68. S.O. Lee, Z. Ma, C.R. Yeh, J. Luo, T.H. Lin, K.P. Lai, S. Yamashita, L. Liang, J. Tian, L. Li, Q. Jiang, C.K. Huang, Y. Niu, S. Yeh, and C. Chang New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells J Mol Cell Biol 5 2013 14 26
69. M.H. Wu, W.L. Ma, C.L. Hsu, Y.L. Chen, J.H. Ou, C.K. Ryan, Y.C. Hung, S. Yeh, and C. Chang Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription Sci Transl Med 2 2010 32ra35
70. W.L. Ma, C.L. Hsu, M.H. Wu, C.T. Wu, C.C. Wu, J.J. Lai, Y.S. Jou, C.W. Chen, S. Yeh, and C. Chang Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma Gastroenterology 135 2008 947 955 955.e1-5
71. H. Miyamoto, Z. Yang, Y.T. Chen, H. Ishiguro, H. Uemura, Y. Kubota, Y. Nagashima, Y.J. Chang, Y.C. Hu, M.Y. Tsai, S. Yeh, E.M. Messing, and C. Chang Promotion of bladder cancer development and progression by androgen receptor signals J Natl Cancer Inst 99 2007 558 568
72. J.J. Lai, K.P. Lai, K.H. Chuang, P. Chang, I.C. Yu, W.J. Lin, and C. Chang Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression J Clin Invest 119 2009 3739 3751
73. Z. Yang, Y.J. Chang, I.C. Yu, S. Yeh, C.C. Wu, H. Miyamoto, D.E. Merry, G. Sobue, L.M. Chen, S.S. Chang, and C. Chang ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor Nat Med 13 2007 348 353